for the manufacture of a medicament for use in combination with ~~a treatment capable of promoting cervical ripening or promoting myometrial contractions of the uterus~~prostaglandin or oxytocin in the induction of women into labor, wherein the women have been elected for labor induction.

for the manufacture of a medicament for use in combination with prostaglandin or oxytocin in the induction of women into labor, wherein the women have been elected for labor induction.

2. The use according to claim 1, wherein the prostaglandin is selected from the group consisting of dinoprostone (PGE2) and misoprostol.

3. The use according to claim 1, wherein the women have a ripened cervix, but are absent of myometrial contractions.

4. The use according any one of claims 1 to 3, wherein the predominantly occurring polysaccharide chains have between 6 and 12 disaccharide units with molecular weights from 3.6 to 7.2 kDa.

5. The use according to any one of claims 1 to 4, comprising modified glucosamines present as signals in the interval of 5.0 to 6.5 ppm in a ^{1}H-NMR spectrum with an intensity (% ratio) of less than 4 % in relation to the signal at 5.42 ppm from native heparin.

6. The use according claim 5, wherein the modified glucosamine signals are present at 5.95 ppm and 6.15 ppm in the ^{1}H-NMR spectrum.

7. The use according to any one of claims 5 or 6, wherein less than 1% of the total content of glucosamines is modified.

8. The use according to any one of claims 1 to 7, essentially free of intact non-sulfated iduronic and/or glucuronic acids.

for the manufacture of a medicament for use in combination with a treatment capable of promoting cervical ripening or promoting myometrial contractions of the uterus in the induction of women into labor.

2. The use according to claim 1, wherein the treatment is an agent for promoting cervical ripening in women with an unripe cervix.

3. The use according to claim 2, wherein the treatment of promoting cervical ripening comprises administration of a prostaglandin.

4. The use according to claim 3, wherein the prostaglandin is selected from the group consisting of dinoprostone (PGE2) and misoprostol.

5. The use according to any one of claims 1 to 4, wherein the treatment is an agent capable of promoting myometrial contractions of the uterus.

6. The use according to claim 5, wherein the women have a ripened cervix, but are absent of myometrial contractions.

7. The use according to claim 5 or 6, wherein the agent capable of promoting myometrial contractions is oxytocin.

8. The use according any one of claims 1 to 7, wherein the predominantly occurring polysaccharide chains have between 6 and 12 disaccharide units with molecular weights from 3.6 to 7.2 kDa.

9. The use according to any one of claims 1 to 8, comprising modified glucosamines present as signals in the interval of 5.0 to 6.5 ppm in a ^{1}H-NMR spectrum with an intensity (% ratio) of less than 4 % in relation to the signal at 5.42 ppm from native heparin.

10. The use according claim 9, wherein the modified glucosamine signals are present at 5.95 ppm and 6.15 ppm in the ^{1}H-NMR spectrum.

11. The use according to any one of claims 9 or 10, wherein less than 1% of the total content of glucosamines is modified.

12. The use according to any one of claims 1 to 11, essentially free of intact non-sulfated iduronic and/or glucuronic acids.

13. The use according to anyone of claims 1 to 12, wherein the chemically modified

heparin or heparan sulfate is for use as an add-on therapy to the treatment capable of promoting cervical ripening or promoting myometrial contractions of the uterus.